logo

Nabriva Therapeutics (NBRV)



Trade NBRV now with
  Date
  Headline
1/14/2019 7:09:15 AM Nabriva Therapeutics Updates On PDUFA Date For Intravenous CONTEPO
12/21/2018 7:04:45 AM Nabriva Therapeutics Announces Closing Of Up To $75 Mln Term Loan
12/20/2018 7:04:11 AM Nabriva Therapeutics Submits NDA For Lefamulin To Treat Community-Acquired Bacterial Pneumonia In Adults
11/6/2018 7:12:19 AM Nabriva Therapeutics Q3 Net Loss $52.8 Mln Or $0.90/Shr Vs Loss Of $22.3 Mln Or $0.79/Shr Last Year
9/28/2018 7:12:00 AM Nabriva Therapeutics To Present Data At ID Week Demonstrating Potential Of Lefamulin For CABP And CONTEPO
8/9/2018 7:19:07 AM Nabriva Therapeutics Q2 Net Loss $17.8 Mln Or $0.44/shr Vs Loss Of $14.6 Mln Or $0.54/shr Last Year
7/26/2018 8:07:35 PM Nabriva Therapeutics Prices Public Offering Of 18.18 Mln Shares At $2.75/shr
7/25/2018 4:05:10 PM Nabriva Therapeutics Announces Proposed Public Offering Of Ordinary Shares
7/24/2018 4:03:36 PM Nabriva Therapeutics Acquires Of Zavante Therapeutics
5/21/2018 7:36:52 AM Nabriva Therapeutics Announces Positive Topline Results From Pivotal Phase 3 Clinical Trial Of Oral Lefamulin
5/16/2018 11:47:52 AM Wedbush Is Raising Nabriva Therapeutics (NBRV) FY18 Rev. Estimate To 16.3 M From 5.0 M
5/16/2018 11:47:38 AM Wedbush Is Lowering Nabriva Therapeutics (NBRV) Q4 18 Rev. Estimate To 1.0 M From 1.4 M
5/16/2018 11:47:25 AM Wedbush Is Increasing Nabriva Therapeutics (NBRV) Q3 18 Rev. Estimate To 6.7 M From 1.1 M
5/16/2018 11:47:11 AM Wedbush Is Lowering Nabriva Therapeutics (NBRV) Q2 18 Rev. Estimate To 1.0 M From 1.4 M
5/16/2018 11:46:46 AM Wedbush Is Raising Nabriva Therapeutics (NBRV) FY18 Estimate To -1.55 From -2.85
5/16/2018 11:46:25 AM Wedbush Is Increasing Nabriva Therapeutics (NBRV) Q4 18 Estimate To -0.41 From -0.61
5/16/2018 11:46:11 AM Wedbush Is Increasing Nabriva Therapeutics (NBRV) Q3 18 Estimate To -0.32 From -0.75
5/16/2018 11:45:55 AM Wedbush Is Increasing Nabriva Therapeutics (NBRV) Q2 18 Estimate To -0.46 From -0.74